Is 'Leptin Resistance' Another Key Resistance to Manage Type 2 Diabetes?
| Autor: | Lisse Angarita, Luis D'Marco, Mervin Chávez-Castillo, Manuel Nava, Valmore Bermúdez, Milagros Rojas, Yaneth Herazo, Jose L. Perez, Cristobal Espinoza, Joselyn Rojas, Juan Salazar, Diana Marcela Rojas, Ángel Ortega, Maricarmen Chacín |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Leptin medicine.medical_specialty Endocrinology Diabetes and Metabolism media_common.quotation_subject Leptin resistance Hypothalamus Amylin Adipokine 030209 endocrinology & metabolism Type 2 diabetes 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Adipokines Internal medicine medicine Animals Humans Glucose homeostasis Obesity media_common business.industry Diabetes Type 2 Diabetes Mellitus Appetite medicine.disease 030104 developmental biology Hyperleptinemia Diabetes Mellitus Type 2 Insulin Resistance business |
| Zdroj: | Current Diabetes Reviews Vol. 16, Issue 7, 2020 |
| Popis: | Although novel pharmacological options for the treatment of type 2 diabetes mellitus (DM2) have been observed to modulate the functionality of several key organs in glucose homeostasis, successful regulation of insulin resistance (IR), body weight management, and pharmacological treatment of obesity remain notable problems in endocrinology. Leptin may be a pivotal player in this scenario, as an adipokine which centrally regulates appetite and energy balance. In obesity, excessive caloric intake promotes a low-grade inflammatory response, which leads to dysregulations in lipid storage and adipokine secretion. In turn, these entail alterations in leptin sensitivity, leptin transport across the blood-brain barrier and defects in post-receptor signaling. Furthermore, hypothalamic inflammation and endoplasmic reticulum stress may increase the expression of molecules which may disrupt leptin signaling. Abundant evidence has linked obesity and leptin resistance, which may precede or occur simultaneously to IR and DM2. Thus, leptin sensitivity may be a potential early therapeutic target that demands further preclinical and clinical research. Modulators of insulin sensitivity have been tested in animal models and small clinical trials with promising results, especially in combination with agents such as amylin and GLP-1 analogs, in particular, due to their central activity in the hypothalamus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|